NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced the appointment of Dr Cyrille Leperlier to its Board as an independent non-executive Director. NuCana's ProTide technology transforms some of the most widely prescribed chemotherapy agents into more effective and safer medicines.
"We are delighted to welcome Cyrille to NuCana's Board of Directors," said Hugh Griffith, NuCana's Chief Executive Officer and Founder. "He is a recognised expert in oncology drug development, strategic portfolio prioritisation and business development, with extensive leadership experience at a number of global biotechnology and pharmaceutical companies."
Dr Leperlier brings to NuCana over 30 years of experience in the pharmaceutical and biotechnology industry.
Dr Leperlier brings to NuCana over 30 years of experience in the pharmaceutical and biotechnology industry. Most recently, Dr Leperlier served as Senior Scientific Advisor for Sanofi's Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi's acquisition of Genzyme.
Prior to this role, Dr Leperlier served as Medical Director in Japan for Sanofi. Before joining Sanofi, Dr Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles.
Dr Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris.
